Brazil accuses Gilead over 1,421.5% price hike of hep C drug

The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Brazil rules 10-year patent term ‘unconstitutional’

11 May 2021 Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.

Big Pharma

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

Americas

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.